# Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury

> **NCT02669849** · PHASE2,PHASE3 · TERMINATED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 70 (actual)

## Conditions studied

- Cervical Spinal Cord Injury

## Interventions

- **DRUG:** VX-210
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02669849
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-07
- **Primary completion:** 2018-11
- **Final completion:** 2018-11
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2020-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02669849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02669849, "Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02669849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*